Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for a newly hired employee.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for a newly hired employee. The compensation committee approved 15,000 restricted stock units (RSUs) and stock options for 30,000 shares on September 22, 2025.
The RSUs will fully vest after three years, while the stock options will vest one-third after the first year and 1/36th monthly thereafter. The stock options have a seven-year term and an exercise price at Fair Market Value. These grants were made under Lifecore's Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – LFCR
On Sep 24, the first trading day after this news, LFCR closed 10.70% below the previous close.
Data tracked by StockTitan Argus for the Sep 24 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired employee of Lifecore. The RSU award and stock options were granted on September 22, 2025, pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore.
The RSU award and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.
The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.